Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
t3PEw1CTarLPGcQu
